Published Online: Tuesday, January 1, 2008

A new generic-industry joint venture linking New Jersey?based Amneal Pharmaceuticals and India?s Indoco Remedies will result in the marketing of at least 10 generic ophthalmic products in the United States.

Amneal?s role in the partnership will be to prepare and file abbreviated new drug applications for FDA approval and to exclusively market these products throughout the US pharmaceutical market. Indoco will be responsible for manufacturing the generics. Spokesmen for the 2 companies said that Indoco and Amneal have already begun to identify several more ophthalmic products to pursue, as well as other therapeutic categories and dosage forms.

Latest Articles
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Latest Issues